Cultured epidermal skin has become an adjunctive therapy for treatment of major burn injuries, but its effectiveness is greatly limited because of destruction by microbial contamination. To evaluate candidate antimicrobial agents for use with cultured skin, a combined cytotoxicity-antimicrobial assay system was developed for determination of toxicity to cultured human keratinocytes and fibroblasts and for determination of susceptibility or resistance of common burn wound organisms. Candidate agents including chlorhexidine gluconate, polymyxin B, mupirocin, sparfloxacin, or nitrofurazone were tested separately for inhibition of growth of human cells and for inhibitory activity to microorganisms with the wet disk assay. The data showed that (1) chlorhexidine gluconate (0.05%) was uniformly toxic to both cultured human cells and microorganisms; (2) 
Recent advances in the grafting of burns and giant congenital nevi indude cultured alone or in combination with biopolymer implantsP6 or allodermi~.~.~ However, incomplete epidermal barrier and lack of vascular and immune components at the time of grafting make all models9-" of cultured skin more subject to destruction by burn organisms than native skin grafts. These biologic deficiencies also make cultured epidermal keratinocytes more subject to cytotoxicity of topical antimicrobial agents. Most parenteral antimicrobial drugs are effective and have low toxicity, but topical use may induce resistant organisms that complicate treatment of sepsis. Therefore requirements for topical antimicrobial agents for cultured skin are low toxicity to cultured human skin cells, high activity against common burn wound organisms, and no overlap of activity with parenteral drugs.
Assays for agents that meet these requirements have tested cytotoxicity to cultured human fibroblasts12 or keratinocytes,13 antimicrobial activity on rni~roorganisms,~~'~ or spectra of toxicity to combinations of fibroblasts and burn organism^.'^-^^ This artide describes a combined cytotoxicity-antirnicrobid assay system in which candidate agents may be tested for toxicity to cultured human epidermal keratinocytes and fibroblasts and for antimicrobial activity to common burn wound organisms. Results of this study also identifjr candidate agents that qualifjr for evaluation in vivo with cultured skin. 
MATERIAL AND METHODS
Experimental Design. The experimental algorithm by which candidate antimicrobial agents are qualhed as having no or low toxicity to cultured human skin cells, and antimicrobial activity to common burn wound organisms has been described elsewhere.'' After determination of the highest concentration of a candidate antimicrobial agent that was not cytotoxic to cultured keratinocytes and fibroblasts, an equal or lower concentration was tested for antimicrobial activity on representative samples of microorganisms isolated from burn wounds.
Antimicrobial Agents. All antimicrobial agents in pure powder form were diluted to the experimental concentrations with sterile saline solution for susceptibility testing against microorganisms or in aqueous culture medium (see following) for cytotoxicity testing. To increase the solubility of nitrofurazone the initial amount of dry powder was dissolved in 1 ml propylene glycol before it was diluted in saline solution or culture medium to the experimental concentrations. For human cell assays each agent was diluted serially at half-log concentrations to 100 times the highest test dose into respective growth media for keratinocytes or fibroblasts. For antimicrobial assays the clinically relevant concentrations were tested on clinical isolates of burn organisms (see following).
Human Cell Assay. Human cpidermal keratinocytes and dermal fibroblasts were isolated from surgical discard tissue obtained with approval of the University of Cincinnati Institutional Review Board. Epidermal keratinocytes were grown as described p r e v i o~s l y~' ,~~ in serum-free MCDB (molecular, cellular, and developmental biology) 153 medium with 0.2 rnrnol/L calcium and increased amino acids23; they were supplemented with 0.5% bovine pituitary extract, 1 nglml epidermal growth factor, 5 pglml insulin, and 0.5 ~g / m l hydrocortisone. Dermal fibroblasts were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, 1 nglml epidermal growth factor, 5 pglml insulin, and 0.5 pglml hydrocortisone. Keratinocytes or fibroblasts were inoculated into 60 rnrn petri dishes at 2 x lo4 cells/dish (1 x lo3 cells/cm2) into the respective culture media described previously. These media also contained a combination of penicillin (10,000 Ulml), streptomycin (10,000 pglml), and amphotericin B (25 pglml) . Cells were incubated 4 days at 37" C in 5% C 0 2 with saturated humidity. Cell counts were performed on a Coulter model Z,, particle counter (Coulter Electronics, Inc., Hialeah, Fla.). On day 4 media were changed to remove penicillin-streptomycin-amphotericin B, baseline cell counts were performed, and test compounds were titrated into the cell cultures. Cells were incubated 4 additional days, harvested, and counted.13 Each experimental condition was performed in triplicate, and each experiment was repeated once (n = 6).
Wet Disk Assay. 
RESULTS
Human Cell Assays. Table 1 lists the pH and osmolarity of the highest concentrations of agents tested on human skin cells. Ranges of pH were 7.36 for chlorhexidine to 7.66 for sparfloxacin. Osmolarity ranged from 328 for polymyxin B to 335 for mupirocin except for nitrohazone, which was very hypertonic at 744 mOsm. Figure 1 shows that chlorhexidine gluconate at concentrations as low as 0.005% (wt Ivol) inhibits growth of both fibroblasts and keratinocytes. Higher concentrations of chlorhexidine gluconate (i.e., 0.15% to 0.5%) generated counts that were increased by artifact. Those concentrations formed particulate precipitate that was counted by the Coulter counter but contained no cultured cells. Titration of polymyxin B (Figure 2 ) over two log dilutions cause no inhibition of growth of fibroblasts, but did cause significant growth inhibition of keratinocytes at the highest test dose (4000 Ulml). Figure 3 shows that mupirocin (160 pglml) was completely nontoxic to both fibroblasts and keratinocytes at the concentrations tested. Similarly sparfloxacin was nontoxic to cell growth at all concentrations up to 100 pglml as shown in Figure  4 . Nitrofurazone ( Figure 5 ) showed concentrationdependent toxicity to both fibroblasts and keratinocytes and had very limited solubility at contentrations higher than those clinically relevant (0.02% Iwt). Although these results do not distinguish whether detected cytotoxicity results from nitrofurazone or the propylene glycol vehicle, toxicity of the formulated agent at clinically relevant concentrations disqualifies this compound for use with cultured skin grafts.
Wet Disk Assays. Figure 2 . Dose response sf cultured human keratinocytes and fibroblasts to polymyxin R. Test conditions were initiated on culture day 4. Cytotoxieity to keratinocytes is detected at 4000 Ulml. Figure 3 . Dose response of cultured human keratinocytes and fibroblasts to sparflsxacitl. Test conditions were initiated on culture day 4, Low but significant amounts of growth inhibition to keratinocytes occurs at 100 p,g/ml. All otl~er concentrations tested are nontoxic to both cell types. Figure 4 . Dose response of cultured human keratinocytes and fibroblasts to mupirocin. Test conditiolis were initiated on culture day 4. No cytotoxicity is detected at concentrations tested. Figure 5 . Dose response of cultured human keratinocytes and fibroblasts to nitrofi~razone in propylcne glycol. Test conditions were initiated on culturc day 4. Nitrofura7x)nc formulated in propylene glycol generates concentration-dependent cytotoxicity to both cell types.
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organisms than arc convcntional skin grafts. This gcncral limitation of cultured skin rcsults from incomplctc epidermal barricr at grafting, abscncc of vascular plexus and immune cclls, and conscqucnt protraction of engraftmcnt by scvcral days. These biologic deficiencies of culturcd skin account for its vulnerability to microbial destruction and impose additional surgical and postsurgical rcquiremcnts for protcction of the culturcd cclls, until stable vasculaturc dcvclops and epidermal tissuc bccomcs kcratinizcd. Howcvcr, it has bcen shown12*1"19 that topical antimicrobial agcnts (i.e., mafcnidc acetate, silver sulfadiazine, clorhcxidine gluconatc [Hibiclens] ) that are used succcssfilly with native skin grafts are toxic to cultured keratinocytcs and are associated with failure of culturcd grafts. Therefore quantitative assays arc nceded to select antimicrobial agcnts in appropriate dosagcs that have no or low toxicity to transplanted cells and that rctain a broad spcctrum of antimicrobial activity. Results presented hcrc dcmonstrate that a combined assay system can determine conccntration rangcs of candidate drugs that have low toxicity to human cclls and rctain antimicrobial activity against burn wound microorganisms. This combined assay system can both qualify and disqualify either individual agents or combinations of agents for topical use with cultured skin cells for wound treatment. Although chlorhexidine is uniformly effective against a wide variety of burn organisms, it is disqualified from consideration, because it is also highly cytotoxic to cultured keratinocytes and fibroblasts ( Figure 1 , Table 2 ). Conversely polymyxin B, sparfloxacin, and mupirocin are qualified as antibiotics that. have low toxicity to skin cells within certain concentration ranges and retention of antimicrobial activity against burn organisms in those ranges (Figures 2, 3, 4 ; Table 2 ). In related studies combined cytotoxicity-antimicrobial assays also identified that addition of an antimycotic agent, nystatin, to antibiotic formulations does not increase cytotoxicity to transplanted cells nor reduce the antimicrobial activities of selected antibiotics.17 In addition, amphotericin B in low concentrations (i.e., 1 ~g l r n l ) is not cytotoxic to cultured cells24 and can be used to manage fungal contamination in wounds. Therefore these assays identifjr stringent requirements for selection of antimicrobial agents that may avoid cytotoxicity to cultured skin. However, it is expected that as cultured skin substitutes are developed with more biologic homology to native skin (i.e., improved keratinization and barrier function), stringency for clinical management of cultured and native skin grafts may also become more homologous.
Other factors not addressed in this study that are important to clinical management of microbial contamination of cultured skin include but are not limited to (1) nonoverlapping antimicrobial activity with parented treatment of burn sepsis; (2) evaluation of combinations of agents to cover both grampositive and gram-negative organisms; (3) delivery of adequate levels of antimicrobial formulations to the site of the microbial contamination; and (4) microbial monitoring of wound sites chosen for patient grafting with cultured skin cells to determine the types and sensitivities of organisms to noncytotoxic formulations of topical antimicrobials. Delivery of novel formulations to the site of contamination is a complex question that requires dedicated studies to address. To understand and regulate drug delivery future studies should address wound bed preparation and pretreatment, vehicles and protocols for adrninistration of novel formulations, penetration and halflife of compounds in the wound, and effective dose at the graft-wound interface. Finally, monitoring of patient wounds to determine type and sensitivity of microbial contamination is a routine clinical procedure with which the cytotoxicity-antimicrobial assays described here can be easily coordinated. Any novel formulations of topical antimicrobial^^^-^' qualified by the assays described here may be added to the sensitivity testing of organisms for identification of whether the formulations are suitable for use with cultured skin in particular patient cases.
In conclusion this study demonstrates a direct and inexpensive assay system by which topical antimicrobial agents may be selected for use with cultured skin grafts for burn wound treatment. Data from this assay system show that three antibiotics (polymyxin B, mupirocin, sparfloxacin) within specific concentration ranges are nontoxic to cultured human cells and are effective against a broad spectrum of burn organisms and that chlorhexidine gluconate and nitrofurazone are cytotoxic to cultured skin cells at clinically relevant concentrations. The data suggest that polymyxin B, mupirocin, and sparfloxacin alone or in combination may have prospective use as topical antimicrobials on cultured skin for burns. Application of these findings may improve engraftment and
